SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-062897
Filing Date
2023-11-13
Accepted
2023-11-13 16:02:10
Documents
67
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q spro-20230930.htm   iXBRL 10-Q 3213525
2 EX-3.1 spro-ex3_1.htm EX-3.1 189310
3 EX-31.1 spro-ex31_1.htm EX-31.1 11077
4 EX-31.2 spro-ex31_2.htm EX-31.2 11123
5 EX-32 spro-ex32.htm EX-32 9706
  Complete submission text file 0000950170-23-062897.txt   10272460

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT spro-20230930_cal.xml EX-101.CAL 43974
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT spro-20230930.xsd EX-101.SCH 73008
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT spro-20230930_pre.xml EX-101.PRE 406435
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT spro-20230930_def.xml EX-101.DEF 244052
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT spro-20230930_lab.xml EX-101.LAB 517549
61 EXTRACTED XBRL INSTANCE DOCUMENT spro-20230930_htm.xml XML 1568239
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38266 | Film No.: 231398469
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences